Cabaletta Bio (CABA) Competitors

$3.65 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.66 +0.01 (+0.25%)

As of 05/22/2026 07:58 PM Eastern

CABA vs. GHRS, IMTX, KALV, IMCR, and MAZE

Should you buy Cabaletta Bio stock or one of its competitors? MarketBeat compares Cabaletta Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cabaletta Bio include GH Research (GHRS), Immatics (IMTX), KalVista Pharmaceuticals (KALV), Immunocore (IMCR), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry.

How does Cabaletta Bio compare to GH Research?

Cabaletta Bio (NASDAQ:CABA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Cabaletta Bio has a beta of 3.18, suggesting that its share price is 218% more volatile than the broader market. Comparatively, GH Research has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

In the previous week, GH Research had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 9 mentions for GH Research and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.50 beat GH Research's score of -0.86 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Cabaletta Bio presently has a consensus target price of $15.50, indicating a potential upside of 324.66%. GH Research has a consensus target price of $40.38, indicating a potential upside of 82.53%. Given Cabaletta Bio's higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

GH Research is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

GH Research's return on equity of -19.36% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
GH Research	N/A	-19.36%	-18.73%

56.9% of GH Research shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

GH Research beats Cabaletta Bio on 9 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Immatics?

Immatics (NASDAQ:IMTX) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Cabaletta Bio had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for Cabaletta Bio and 1 mentions for Immatics. Cabaletta Bio's average media sentiment score of 0.50 beat Immatics' score of 0.00 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Immatics	Neutral
Cabaletta Bio	Positive

Immatics currently has a consensus price target of $19.00, indicating a potential upside of 63.51%. Cabaletta Bio has a consensus price target of $15.50, indicating a potential upside of 324.66%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Immatics has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.18, suggesting that its share price is 218% more volatile than the broader market.

64.4% of Immatics shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cabaletta Bio has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Cabaletta Bio	N/A	-131.58%	-96.46%

Cabaletta Bio has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	28.53	-$222.26M	-$1.99	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Summary

Cabaletta Bio beats Immatics on 9 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to KalVista Pharmaceuticals?

Cabaletta Bio (NASDAQ:CABA) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Cabaletta Bio's return on equity of -131.58% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Cabaletta Bio has a beta of 3.18, suggesting that its stock price is 218% more volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Cabaletta Bio currently has a consensus price target of $15.50, indicating a potential upside of 324.66%. KalVista Pharmaceuticals has a consensus price target of $30.60, indicating a potential upside of 14.22%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, KalVista Pharmaceuticals had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 5 mentions for KalVista Pharmaceuticals and 2 mentions for Cabaletta Bio. KalVista Pharmaceuticals' average media sentiment score of 0.89 beat Cabaletta Bio's score of 0.50 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KalVista Pharmaceuticals has higher revenue and earnings than Cabaletta Bio. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
KalVista Pharmaceuticals	$49.08M	29.06	-$109.52M	-$3.46	N/A

Summary

Cabaletta Bio beats KalVista Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Cabaletta Bio compare to Immunocore?

Cabaletta Bio (NASDAQ:CABA) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Cabaletta Bio has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Immunocore	-6.68%	-7.07%	-2.55%

Cabaletta Bio presently has a consensus target price of $15.50, indicating a potential upside of 324.66%. Immunocore has a consensus target price of $57.75, indicating a potential upside of 100.31%. Given Cabaletta Bio's higher possible upside, equities research analysts plainly believe Cabaletta Bio is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Immunocore has higher revenue and earnings than Cabaletta Bio. Immunocore is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Immunocore	$400.02M	3.65	-$35.51M	-$0.55	N/A

84.5% of Immunocore shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cabaletta Bio has a beta of 3.18, indicating that its share price is 218% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

In the previous week, Cabaletta Bio had 2 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Cabaletta Bio and 0 mentions for Immunocore. Immunocore's average media sentiment score of 1.00 beat Cabaletta Bio's score of 0.50 indicating that Immunocore is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Positive
Immunocore	Positive

Summary

Immunocore beats Cabaletta Bio on 10 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Maze Therapeutics' return on equity of -36.62% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Cabaletta Bio	N/A	-131.58%	-96.46%

Maze Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 156.01%. Cabaletta Bio has a consensus target price of $15.50, indicating a potential upside of 324.66%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Maze Therapeutics has higher revenue and earnings than Cabaletta Bio. Maze Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.52	-$131.12M	-$2.53	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

In the previous week, Maze Therapeutics had 19 more articles in the media than Cabaletta Bio. MarketBeat recorded 21 mentions for Maze Therapeutics and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.50 beat Maze Therapeutics' score of -0.68 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.18, suggesting that its share price is 218% more volatile than the broader market.

Summary

Maze Therapeutics beats Cabaletta Bio on 8 of the 13 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$595.15M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.86	18.74	21.22	25.66
Price / Sales	N/A	323.98	562.28	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	5.79	7.09	10.31	7.14
Net Income	-$167.86M	$24.45M	$3.57B	$335.98M
7 Day Performance	11.62%	6.38%	6.43%	4.15%
1 Month Performance	23.73%	2.43%	3.57%	2.54%
1 Year Performance	108.57%	62.98%	34.07%	35.06%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.4102 of 5 stars	$3.65 flat	$15.50 +324.7%	+108.6%	$595.15M	N/A	N/A	50
GHRS GH Research	2.9034 of 5 stars	$21.68 +1.4%	$41.00 +89.1%	+98.0%	$1.47B	N/A	N/A	10	Gap Up
IMTX Immatics	2.1218 of 5 stars	$10.62 -2.3%	$19.00 +78.9%	+127.4%	$1.46B	$54.60M	N/A	260
KALV KalVista Pharmaceuticals	2.9355 of 5 stars	$26.76 +0.1%	$30.60 +14.3%	+133.6%	$1.42B	$49.08M	N/A	100
IMCR Immunocore	3.3409 of 5 stars	$28.37 +1.1%	$57.75 +103.6%	-7.5%	$1.42B	$400.02M	N/A	320	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. GHRS, IMTX, KALV, IMCR, and MAZE

How does Cabaletta Bio compare to GH Research?

Summary

How does Cabaletta Bio compare to Immatics?

Summary

How does Cabaletta Bio compare to KalVista Pharmaceuticals?

Summary

How does Cabaletta Bio compare to Immunocore?

Summary

How does Cabaletta Bio compare to Maze Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. GHRS, IMTX, KALV, IMCR, and MAZE

How does Cabaletta Bio compare to GH Research?

Which has more risk and volatility, CABA or GHRS?

Does the media favor CABA or GHRS?

Do analysts prefer CABA or GHRS?

Which has better valuation & earnings, CABA or GHRS?

Is CABA or GHRS more profitable?

Do institutionals and insiders believe in CABA or GHRS?

Summary

How does Cabaletta Bio compare to Immatics?

Does the media prefer IMTX or CABA?

Do analysts recommend IMTX or CABA?

Which has more risk & volatility, IMTX or CABA?

Do insiders and institutionals have more ownership in IMTX or CABA?

Is IMTX or CABA more profitable?

Which has better valuation and earnings, IMTX or CABA?

Summary

How does Cabaletta Bio compare to KalVista Pharmaceuticals?

Is CABA or KALV more profitable?

Which has more risk & volatility, CABA or KALV?

Do analysts recommend CABA or KALV?

Does the media prefer CABA or KALV?

Which has better valuation and earnings, CABA or KALV?

Summary

How does Cabaletta Bio compare to Immunocore?

Is CABA or IMCR more profitable?

Do analysts recommend CABA or IMCR?

Which has higher earnings & valuation, CABA or IMCR?

Do institutionals and insiders believe in CABA or IMCR?

Which has more volatility and risk, CABA or IMCR?

Does the media refer more to CABA or IMCR?

Summary

How does Cabaletta Bio compare to Maze Therapeutics?

Is MAZE or CABA more profitable?

Do analysts prefer MAZE or CABA?

Which has higher valuation & earnings, MAZE or CABA?

Does the media prefer MAZE or CABA?

Which has more volatility & risk, MAZE or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools